The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…

Lorbrena from Pfizer was initially FDA indicated to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive based an FDA-approved test. In March, Pfizer announced that the drug had won an expanded indication for use as a first-line therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell…